• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Turkey Pharmaceuticals & Healthcare Report Q1 2009 - Product Image

Turkey Pharmaceuticals & Healthcare Report Q1 2009

  • ID: 689933
  • January 2009
  • Region: Turkey
  • 86 Pages
  • Business Monitor International

FEATURED COMPANIES

  • Abdi Ibrahim
  • AstraZeneca
  • Biomeks
  • Merck & Co
  • Pfizer
  • Sanofi-Aventis
  • MORE

BMI's Turkey Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Turkey's pharmaceuticals and healthcare industry.

Turkey represents one of the most dynamic pharmaceutical markets in Central and Eastern Europe (CEE) thanks to its large value and strong growth in recent years. After extending our forecasts for the Q109 report, BMI believes that total pharmaceutical expenditure will reach a value of US$22bn by 2013, representing average annual growth of 10%. While growth and value remain high, per capita spending will still be relatively low by the end of 2013, relative to more developed markets.

In BMI’s Business Environment Rankings for CEE, Turkey ranks joint fourth with Russia and Estonia. While market scores are among the strongest in the region, weak risk scores prevent the country from topping the rankings. In 2008, Turkey was placed on the United States Trade Representatives Special 301 Watch List, having received an improved appraisal. The USTR cautioned the health and patent authorities to prevent patent abuse. In 2009 there are likely to be improvements in the country’s score with the implementation READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abdi Ibrahim
  • AstraZeneca
  • Biomeks
  • Merck & Co
  • Pfizer
  • Sanofi-Aventis
  • MORE

Executive Summary
- Turkey Pharmaceuticals And Healthcare Industry SWOT
- Turkey Political SWOT
- Turkey Economic SWOT
- Turkey Business Environment SWOT

Pharmaceutical Business Environment Rating
- Regional Pharma Business Environment Ratings
- Limits Of Potential Returns
- Risks To Realisation Of Returns

Turkey – Market Summary

Regulatory Regime
- Intellectual Property Regime
- Intellectual Property Shortcomings
- Counterfeit Drugs
- Pricing Regime
- Table: Turkish Pharmacy And Wholesale Mark-Ups
- Reimbursement Regime

Sector Developments
- Epidemiology
- Table: Disease Burden In CEE
- Healthcare Sector
- Healthcare Expenditure
- Healthcare Sector Reforms
- Health Insurance
- Pharmaceutical Sector
- Pharmaceutical Retail And Distribution
- Recent Pharmaceutical Sector Developments
- International Co-operation
- Research And Development Sector
- Table: Turkey's New R&D Law
- Medical Devices
- Recent Medical Devices Industry Developments

Industry Forecast Scenario
- Overall Market Forecast
- Table: Turkey – Drug Expenditure Indicators, 2004-2013
- Key Growth Factors – Industry
- Table: Turkey – Healthcare Expenditure Indicators, 2004-2013
- Key Growth Factors – Macroeconomic
- Table: Turkey – Economic Activity
- Prescription Market Forecast
- Table: Turkey – Prescription Market Indicators, 2004-2013 (TRYmn unless otherwise stated)
- OTC Market Forecast
- Table: Turkey – OTC Market Indicators, 2004-2013 (TRYmn unless otherwise stated)
- Patented Drug Market Forecast
- Table: Turkey – Patented Market Indicators, 2004-2013
- Generic Drug Market Forecast
- Table: Turkey – Generics Market Indicators, 2004-2013
- Export/Import Market Forecasts
- Table: Turkey – Pharmaceutical Trade Indicators, 2004-2013 (US$mn)
- Other Healthcare Data
- Table: Turkey – Other Healthcare Indicators, 2004-2013

Competitive Landscape
- Table: Top 10 Pharmaceutical Companies In Turkey By Market Share, MAT July 2008

Company Profiles
- Novartis
- Sanofi-Aventis
- GlaxoSmithKline
- Pfizer
- Roche
- AstraZeneca
- Bayer
- Merck & Co
- Indigenous Companies
- Abdi Ibrahim
- Eczacibasi Pharmaceuticals
- Sanovel Pharmaceuticals
- EastPharma (formerly Deva Holding)
- Actavis (formerly Fako)
- Biomeks

Country Snapshot: Turkey Demographic Data
- Section 1: Population
- Table: Demographic Indicators, 2005-2030
- Table: Rural/Urban Breakdown, 2005-2030
- Section 2: Education And Healthcare
- Table: Education, 2002-2005
- Table: Vital Statistics, 2005-2030
- Section 3: Labour Market And Spending Power
- Table: Employment Indicators, 2001-2006
- Table: Consumer Expenditure, 2000-2012 (US$)

BMI Forecast Modelling
- How We Generate Our Pharmaceutical Industry Forecasts
-- Pharmaceutical Business Environment Ratings Methodology
-- Ratings Overview
-- Table: Pharmaceutical Business Environment Indicators
-- Weighting
-- Table: Weighting Of Components
- Sources

Note: Product cover images may vary from those shown

- Novartis
- Sanofi-Aventis
- GlaxoSmithKline
- Pfizer
- Roche
- AstraZeneca
- Bayer
- Merck & Co
- Abdi Ibrahim
- Eczacibasi Pharmaceuticals
- Sanovel Pharmaceuticals
- EastPharma (formerly Deva Holding)
- Actavis (formerly Fako)
- Biomeks

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

ALSO AVAILABLE

RELATED PRODUCTS

Our Clients

Our clients' logos